2022
DOI: 10.3390/antiox11020280
|View full text |Cite
|
Sign up to set email alerts
|

Hydroxamic Acid as a Potent Metal-Binding Group for Inhibiting Tyrosinase

Abstract: Tyrosinase, a metalloenzyme containing a dicopper cofactor, plays a central role in synthesizing melanin from tyrosine. Many studies have aimed to identify small-molecule inhibitors of tyrosinase for pharmaceutical, cosmetic, and agricultural purposes. In this study, we report that hydroxamic acid is a potent metal-binding group for interacting with dicopper atoms, thereby inhibiting tyrosinase. Hydroxamate-containing molecules, including anticancer drugs targeting histone deacetylase, vorinostat and panobinos… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 69 publications
(88 reference statements)
0
1
0
Order By: Relevance
“…There are several phase trials for three drugs (dasatinib, navitoclax, vorinostat) listed by Adamic-Adar-2 ( Table 7 ), four drugs (vorinostat, navitoclax, dinaciclib, MK-1775) listed by PageRank-2 ( Table 8 ) and all the drugs (paclitaxel, imexon, sulforaphane, vorinostat) predicted by neighborhood scoring ( Table 9 ) for the treatment of melanoma. Some of these predictions suggested by the new DR method have been used in several studies and clinical trials in the search for new treatment alternatives for melanoma(these include: vorinostat: NCT00121225 ( Haas et al, 2014 ; Choi et al, 2022 ; Wang et al, 2018 ; Nihal, Roelke & Wood, 2010 ); MK-1775: ( Margue et al, 2019 ); imexon: NCT00327600 ( Weber et al, 2010 ); paclitaxel: NCT01107665 ( Fruehauf et al, 2018 ).…”
Section: Resultsmentioning
confidence: 99%
“…There are several phase trials for three drugs (dasatinib, navitoclax, vorinostat) listed by Adamic-Adar-2 ( Table 7 ), four drugs (vorinostat, navitoclax, dinaciclib, MK-1775) listed by PageRank-2 ( Table 8 ) and all the drugs (paclitaxel, imexon, sulforaphane, vorinostat) predicted by neighborhood scoring ( Table 9 ) for the treatment of melanoma. Some of these predictions suggested by the new DR method have been used in several studies and clinical trials in the search for new treatment alternatives for melanoma(these include: vorinostat: NCT00121225 ( Haas et al, 2014 ; Choi et al, 2022 ; Wang et al, 2018 ; Nihal, Roelke & Wood, 2010 ); MK-1775: ( Margue et al, 2019 ); imexon: NCT00327600 ( Weber et al, 2010 ); paclitaxel: NCT01107665 ( Fruehauf et al, 2018 ).…”
Section: Resultsmentioning
confidence: 99%
“…Inhibition of tyrosinase has major roles and applications, e.g., in biomedicine, to contrast skin pigmentation disorders like melasma [ 14 , 15 , 16 , 17 ] and in food safety, to prevent enzymatic food oxidative spoilage on storage [ 16 , 17 , 18 , 19 ].…”
Section: Introductionmentioning
confidence: 99%